Skip to main content
Clinical Trials/EUCTR2017-000421-13-NL
EUCTR2017-000421-13-NL
Active, not recruiting
Phase 1

ewborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxideversus intravenous Sildenafil:an international randomized controlled trial - CoDiNOS trial

Erasmus MC0 sites90 target enrollmentJune 7, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Congenital diaphragmatic hernia with pulmonary hypertension
Sponsor
Erasmus MC
Enrollment
90
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 7, 2017
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Erasmus MC

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of CDH and pulmonary hypertension defined as 2 of the
  • following 4 criteria:
  • I. PAP\> 2/3 systemic pressure estimated by echocardiography
  • II. RV dilatation/septal displacement, RV dysfunction \+/\- LV
  • dysfunction
  • III. Pre\-post ductal SpO2 difference \> 10%
  • IV. OI\>20\.
  • Parental informed consent
  • Children born at or after a gestational age of 34 weeks
  • Newborns who received a fetal intervention may be included

Exclusion Criteria

  • Severe chromosomal anomaly, like trisomy 18 or trisomy 13, which
  • may imply a decision to stop or not to start life\-saving medical treatment
  • Severe cardiac anomaly, expected to need corrective surgery in the
  • first 60 days of life (such as transposition of the great arteries, truncus
  • arteriosus, coarctation aortae or double outlet right ventricle)
  • Renal anomalies associated with oligohydramnios
  • Severe orthopaedic and skeletal deformities, which are likely to
  • influence thoracic, and / or lung development (such as chest wall
  • deformities and spine anomalies)
  • Severe anomalies of the central nervous system

Outcomes

Primary Outcomes

Not specified

Similar Trials